Research programme: hypoxia-inducible factor-1 alpha inhibitors - Rexahn

Drug Profile

Research programme: hypoxia-inducible factor-1 alpha inhibitors - Rexahn

Alternative Names: RX-0047; RX-0047 nanoliposomal; RX-0047-N; RX-0047-Nano

Latest Information Update: 22 Dec 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Dec 2010 Preclinical development is ongoing for RX 0047 N
  • 04 Sep 2009 Preclinical development is ongoing for RX-0047-Nano
  • 01 Jul 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top